公开(公告)号：US20090247528A1

公开(公告)日：2009-10-01

申请号：US12430244

申请日：2009-04-27

申请人： Erik H.F. Wong ,  Saeeduddin Ahmed ,  Robert C. Marshall ,  Robert McArthur ,  Duncan P. Taylor ,  Lars Birgerson ,  Pasquale Cetera

发明人： Erik H.F. Wong ,  Saeeduddin Ahmed ,  Robert C. Marshall ,  Robert McArthur ,  Duncan P. Taylor ,  Lars Birgerson ,  Pasquale Cetera

IPC分类号： A61K31/5375 ,  A61P25/00

CPC分类号： A61K31/5375 ,  A61K31/00 ,  A61K31/537

摘要： Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

摘要翻译： 公开了用于治疗患有或预防人遭受生理或精神疾病，病症或抑制去甲肾上腺素再摄取的病症的人的方法和组合物。 组合物包含具有至少约5000的5-羟色胺（Ki）/去甲肾上腺素（Ki）的药理学选择性的化合物。该化合物的实例包括瑞波西汀，更优选为瑞波西汀的光学纯的（S，S）对映异构体。 方法通常包括施用治疗量的这种组合物。 还公开了来自组合物的药物的制剂，以及该组合物在制备药物中治疗患有或预防人类遭受生理或精神疾病，病症或病症的人的用途。